Hello, everyone, and how are you today? We are doing just fine, thank you, now that a warm and shiny sun has risen over the otherwise chilly Pharmalot campus. Moreover, our short people have scurried off to their destinations, our official mascot is happily snoozing on his couch, and our coffee kettle is heating up another cup of stimulation — almond toffee is our choice today. So this brings us to the task at hand, which is to forage for interesting items. Speaking of which, here are some tidbits. Have a lovely day and best of luck. …

Purdue Pharma agreed to settle the state of Oklahoma’s claims that its illegal marketing of the Oxycontin painkiller caused financial devastation to local communities, the first accord in a recent wave of lawsuits stemming from the U.S. opioid crisis, according to Bloomberg News. The settlement comes two months before the scheduled start of a trial against Purdue, Johnson & Johnson (JNJ), and Teva Pharmaceutical (TEVA). Oklahoma claims the three opioid makers understated the risks of prescription painkillers and overstated their benefits, fueling an epidemic.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy